Medace’s client Chemelot InSciTe, announces that they have started the first-in-man clinical trial for a new scoliosis treatment within the project PoSTuRE (Patient Specific Scoliosis Treatment).
The treatment consists of a newly developed GEM Power Cable, and tools for its implantation. This implant can reduce complications caused by the traditional surgical methods and instruments. The new treatment focuses primarily on improving the quality of life of patients with degenerative scoliosis by reducing the number of complications and reoperations resulting from it. The first patients have already successfully undergone surgery. The clinical study is being conducted at the Maastricht UMC+ hospital.
Emiel Staring, Managing Director Chemelot InSciTe: ‘We are very proud to see that our unconventional biomedical collaborative innovation model has paid off and that we have been able to create a fast track to the clinic and to have paved the path from bench to bedside, also for future biomedical innovations to follow.’
Read the full press release on the website of Chemelot InSciTe.